左卡尼丁联合促红素治疗尿毒症血透患者的效果观察

Effect of the L-carnitine combined with erythropoietin for the treatment of uremia patients with hemodialysis

目的观察左卡尼丁联合促红素治疗尿毒症血透患者的临床效果。方法入选2015年4月~2017年4月的尿毒症血透肾性贫血的患者80例,随机的分成对照组与观察组,各40例。对照组在血液透析后应用促红素皮下注射治疗,观察组在透析后采用左卡尼丁联合促红素治疗。治疗后,对两组的临床疗效进行评价与比较。结果治疗后,在血红蛋白和红细胞压积水平方面,观察组明显高于对照组,差异有统计学的意义(P<0.05)。在不良反应发生率方面,观察组与对照组的分别为12.5%与17.5%,两组差异无统计学的意义(P>0.05)。对比两组患者治疗前的NCT-A型下降时间、血氨浓度,差异均无统计学意义;对比两组患者治疗后的NCT-A型下降时间,观察组明显少于对照组,差异有统计学意义(P<0.05);对比两组患者治疗后的血氨浓度,观察组明显低于对照组,差异有统计学意义(P<0.05)。结论左卡尼丁联合促红素治疗尿毒症血透病人的肾性贫血的临床效果显著,值得在临床中推广应用。

Objective To observe the effect of the L-carnitine combined with erythropoietin for the treatment of uremia patients with hemodialysis. Methods From April 2015 to April 2017,80 cases of renal anemia in patients with uremia and hemodialysis were chosen,and were randomly divided into control group and observation group,40 cases in each group.After hemodialysis,the patients of control group were given subcutaneous injection of erysiderin,and patients of the observation group were treated with the combination of L-earnitine combined with erythropoietin. After treatment,the clinical efficacy of two groups were evaluated and compared. Results After treatment,the level of hemoglobin and red blood cells deposited of observation group was significantly higher than those of control group,the difference was statistically significance （P 〈 0.05）.The incidence of adverse reactions were 12.5% and 17.5% in observation group and control group respectively,the difference between the two groups had no statistical significanee（P〉0.05）.The decline time,blood ammonia concentration of NCT-A of two groups before treatment were compared,there were no statistically significant difference,the decline time of NCT - A of the observation group was significantly less than that of control group,and the difference was statistically significant（P 〈 0.05）,the blood ammonia concentration of NCT - A of the observation group was significantly lower than that of control group,and the difference was statistically significant （P 〈 0.05）. Conclusion The clinical effect of L-carnitine combined with erythropoietin on the treatment of renal anemia in patients with uremia has remarkable clinical effect and it is worth promoting the application in clinic.